HPV testing and vaccination in Europe.

Hdl Handle:
http://hdl.handle.net/10147/335772
Title:
HPV testing and vaccination in Europe.
Authors:
Leeson, Simon C; Alibegashvili, Tamar; Arbyn, Marc; Bergeron, Christine; Carriero, Carmine; Mergui, Jean-Luc; Nieminen, Pekka; Prendiville, Walter; Redman, Charles W E; Rieck, Gudrun C; Quaas, Jens; Petry, K Ulrich
Affiliation:
1Department of Obstetrics and Gynaecology, Betsi Cadwaladr University Health Board, Bangor, Gwynedd, UK; 2Department of Gynecology, National Screening Center, Tbilisi, Georgia; 3Unit of Cancer Epidemiology, Scientific Institute of Public Health, Brussels, Belgium; 4Laboratoire Cerba, Paris, France; 5Department of Gynecology and Obstetrics, University of Bari, Bari, Italy; 6Hôpital Tenon, Service de Gynécologie Obstétrique et Médecine de la Reproduction, Paris, France; 7Department of Obstetrics and Gynecology, Helsinki University Hospital, Finland; 8The Beacon Hospital, Sandyford, Dublin, Ireland; 9Department of Obstetrics and Gynaecology, University Hospital of North Staffordshire, Stoke-on-Trent, UK; 10D-18437 Stralsund, Grünthal, Germany; and 11Department of Obstetrics and Gynaecology, Klinikum Wolfsburg, Wolfsburg, Germany.
Citation:
Leeson, S.C. et al., 2014. HPV testing and vaccination in Europe. Journal of Lower Genital Tract Disease, 18 (1) pp 61-9
Journal:
Journal of lower genital tract disease
Issue Date:
Jan-2014
URI:
http://hdl.handle.net/10147/335772
DOI:
10.1097/LGT.0b013e318286b8d3
PubMed ID:
23774078
Abstract:
Current cytology-based screening has a moderate sensitivity to detect cervical intraepithelial neoplasia grade 3 (CIN 3) and cervical cancer even in those states providing rigorous quality control of their cervical screening programs. The impact of vaccination against human papillomavirus (HPV) types 16 and 18 as well as the incorporation of HPV testing on the detection of CIN 3 and cancer is discussed. HPV testing used as a triage for atypical squamous cells of undetermined significance (ASCUS) and low-grade squamous intraepithelial lesions, test of cure after treatment, and HPV-based primary screening may improve current cervical screening programs.HPV testing as a triage test for ASCUS seems to offer an improved sensitivity, with a similar specificity as compared to repeat cytology for diagnosing high-grade CIN and has been recommended throughout most EU states. HPV testing as a triage test for low-grade squamous intraepithelial lesions has a low specificity and is not recommended in most member states. HPV test of cure offers an improved sensitivity compared to cytology for women with persistent cervical precancer after treatment. HPV-based cervical cancer screening is more effective than screening with cytology. The effects of HPV-based screening depend on the organization of the program and on adherence to algorithms for screening triage. Otherwise, it is likely that HPV-based screening will increase the referral rate to colposcopy including more women with no detectable cervical lesion. HPV vaccination will require many years to evaluate any beneficial effects on cervical cancer incidence and mortality.
Item Type:
Article
Language:
en
Keywords:
CERVICAL CANCER; IMMUNISATION
MeSH:
Early Detection of Cancer; Europe; Female; Human Papillomavirus DNA Tests; Humans; Papillomaviridae; Papillomavirus Infections; Papillomavirus Vaccines; Uterine Cervical Neoplasms; Vaccination
ISSN:
1526-0976

Full metadata record

DC FieldValue Language
dc.contributor.authorLeeson, Simon Cen_GB
dc.contributor.authorAlibegashvili, Tamaren_GB
dc.contributor.authorArbyn, Marcen_GB
dc.contributor.authorBergeron, Christineen_GB
dc.contributor.authorCarriero, Carmineen_GB
dc.contributor.authorMergui, Jean-Lucen_GB
dc.contributor.authorNieminen, Pekkaen_GB
dc.contributor.authorPrendiville, Walteren_GB
dc.contributor.authorRedman, Charles W Een_GB
dc.contributor.authorRieck, Gudrun Cen_GB
dc.contributor.authorQuaas, Jensen_GB
dc.contributor.authorPetry, K Ulrichen_GB
dc.date.accessioned2014-11-18T14:53:14Z-
dc.date.available2014-11-18T14:53:14Z-
dc.date.issued2014-01-
dc.identifier.citationLeeson, S.C. et al., 2014. HPV testing and vaccination in Europe. Journal of Lower Genital Tract Disease, 18 (1) pp 61-9en_GB
dc.identifier.issn1526-0976-
dc.identifier.pmid23774078-
dc.identifier.doi10.1097/LGT.0b013e318286b8d3-
dc.identifier.urihttp://hdl.handle.net/10147/335772-
dc.description.abstractCurrent cytology-based screening has a moderate sensitivity to detect cervical intraepithelial neoplasia grade 3 (CIN 3) and cervical cancer even in those states providing rigorous quality control of their cervical screening programs. The impact of vaccination against human papillomavirus (HPV) types 16 and 18 as well as the incorporation of HPV testing on the detection of CIN 3 and cancer is discussed. HPV testing used as a triage for atypical squamous cells of undetermined significance (ASCUS) and low-grade squamous intraepithelial lesions, test of cure after treatment, and HPV-based primary screening may improve current cervical screening programs.HPV testing as a triage test for ASCUS seems to offer an improved sensitivity, with a similar specificity as compared to repeat cytology for diagnosing high-grade CIN and has been recommended throughout most EU states. HPV testing as a triage test for low-grade squamous intraepithelial lesions has a low specificity and is not recommended in most member states. HPV test of cure offers an improved sensitivity compared to cytology for women with persistent cervical precancer after treatment. HPV-based cervical cancer screening is more effective than screening with cytology. The effects of HPV-based screening depend on the organization of the program and on adherence to algorithms for screening triage. Otherwise, it is likely that HPV-based screening will increase the referral rate to colposcopy including more women with no detectable cervical lesion. HPV vaccination will require many years to evaluate any beneficial effects on cervical cancer incidence and mortality.en_GB
dc.language.isoenen
dc.rightsArchived with thanks to Journal of lower genital tract diseaseen_GB
dc.subjectCERVICAL CANCERen_GB
dc.subjectIMMUNISATIONen_GB
dc.subject.meshEarly Detection of Cancer-
dc.subject.meshEurope-
dc.subject.meshFemale-
dc.subject.meshHuman Papillomavirus DNA Tests-
dc.subject.meshHumans-
dc.subject.meshPapillomaviridae-
dc.subject.meshPapillomavirus Infections-
dc.subject.meshPapillomavirus Vaccines-
dc.subject.meshUterine Cervical Neoplasms-
dc.subject.meshVaccination-
dc.titleHPV testing and vaccination in Europe.en_GB
dc.typeArticleen
dc.contributor.department1Department of Obstetrics and Gynaecology, Betsi Cadwaladr University Health Board, Bangor, Gwynedd, UK; 2Department of Gynecology, National Screening Center, Tbilisi, Georgia; 3Unit of Cancer Epidemiology, Scientific Institute of Public Health, Brussels, Belgium; 4Laboratoire Cerba, Paris, France; 5Department of Gynecology and Obstetrics, University of Bari, Bari, Italy; 6Hôpital Tenon, Service de Gynécologie Obstétrique et Médecine de la Reproduction, Paris, France; 7Department of Obstetrics and Gynecology, Helsinki University Hospital, Finland; 8The Beacon Hospital, Sandyford, Dublin, Ireland; 9Department of Obstetrics and Gynaecology, University Hospital of North Staffordshire, Stoke-on-Trent, UK; 10D-18437 Stralsund, Grünthal, Germany; and 11Department of Obstetrics and Gynaecology, Klinikum Wolfsburg, Wolfsburg, Germany.en_GB
dc.identifier.journalJournal of lower genital tract diseaseen_GB
dc.description.fundingNo fundingen
dc.description.provinceLeinsteren
dc.description.peer-reviewpeer-reviewen

Related articles on PubMed

All Items in Lenus, The Irish Health Repository are protected by copyright, with all rights reserved, unless otherwise indicated.